34617-65-7

Basic information

• Product Name: 5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE
• Synonyms: 5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE;5-amino-3-chloro-2-Pyrazinecarbonitrile
• CAS NO: 34617-65-7
• Molecular Formula: C₅H₃ClN₄
• Molecular Weight: 154.56
• EINECS: 604-604-1
• Mol File: 34617-65-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE(34617-65-7)
• EPA Substance Registry System: 5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE(34617-65-7)

Safety Data

• Hazardous Substances Data: 34617-65-7(Hazardous Substances Data)

Usage

Description

5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE is an organic compound that serves as a crucial reagent in the pharmaceutical industry. It is characterized by its unique molecular structure, which includes an amino group, a chloro substituent, and a carbonitrile functional group. These features contribute to its reactivity and utility in the synthesis of various compounds, particularly in the development of orally bioavailable CHK1 inhibitors.

Uses

Used in Pharmaceutical Industry:
5-AMINO-3-CHLOROPYRAZINE-2-CARBONITRILE is used as a reagent for the synthesis of orally bioavailable CHK1 inhibitors. These inhibitors play a significant role in the treatment of cancer, as they target the checkpoint kinase 1 (CHK1) enzyme, which is involved in the regulation of cell cycle progression and DNA repair. By inhibiting CHK1, these compounds can potentially enhance the effectiveness of DNA-damaging anticancer therapies and overcome drug resistance in cancer cells.

Upstream product

• 925678-00-8 6-chloro-5-iodo-pyrazin-2-ylamine 
• 557-21-1 zinc(II) cyanide 
• 173253-42-4 2-chloro-3-bromo-6-aminopyrazine 
• 34617-64-6 5-amino-3-chloro-pyrazine-2-carbaldehyde O-acetyl-oxime 

Downstream Products

• 1430840-87-1 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one 
• 1430840-13-3 6-[1-(3-methoxyazetidin-1-yl)-ethyl]-3-phenyl-7H-imidazo[1,5-a]pyrazin-8-one 
• 1430840-01-9 3-phenyl-6-(3-phenylazetidin-1-ylmethyl)-7H-imidazo-[1,5-a]pyrazin-8-one 
• 1430841-42-1 6-acetyl-3-phenyl-7H-imidazo[1,5-a]pyrazin-8-one 
• 1430841-41-0 1-(8-methoxy-3-phenyl-imidazo[1,5-a]pyrazin-6-yl)-ethanone 
• 1430841-40-9 8-methoxy-3-phenylimidazo[1,5-a]pyrazine-6-carboxylic acid methoxy-methyl-amide 
• 1430841-39-6 6-chloromethyl-3-phenyl-7H-imidazo[1,5-a]pyrazin-8-one 
• 1430841-38-5 6-(chloromethyl)-8-methoxy-3-phenylimidazo[1,5-a]pyrazine 
• 1430841-37-4 (8-methoxy-3-phenylimidazo[1,5-a]pyrazin-6-yl)methanol 
• 1430841-36-3 methyl 8-methoxy-3-phenylimidazo[1,5-a]pyrazine-6-carboxylate 
• 1430841-35-2 6-iodo-8-methoxy-3-phenylimidazo[1,5-a]pyrazine 
• 1430841-34-1 N-((5-iodo-3-methoxypyrazin-2-yl)methyl)benzamide 

Relevant articles and documents

PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES

The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.

NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE

Provided are new biphenyl derivatives of formula (Ia). These compounds act as aromatase and sulfatase inhibitors. They are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, provided are processes for the preparation of these compounds and pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing

Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines demonstrates how fragment-growing and scaffold morphing strategies arising from a structure-based understanding of CHK1 inhibitor binding can be combined to successfully progress fragment-derived hit matter to compounds with activity in vivo. The challenges of improving CHK1 potency and selectivity, addressing synthetic tractability, and achieving novelty in the crowded kinase inhibitor chemical space were tackled by multiple scaffold morphing steps, which progressed through tricyclic pyrimido[2,3-b] azaindoles to N-(pyrazin-2-yl)pyrimidin-4-amines and ultimately to imidazo[4,5-c]pyridines and isoquinolines. A potent and highly selective isoquinoline CHK1 inhibitor (SAR-020106) was identified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice. (Figure presented)